Kardiologie up2date 2016; 12(01): 21-23
DOI: 10.1055/s-0041-108112
Hotline – Thrombozyten und Gerinnungssystem bei kardiovaskulären Erkrankungen
© Georg Thieme Verlag KG Stuttgart · New York

Direkte orale Antikoagulanzien – wichtige Unterschiede und Kerndaten

M. Hubald
,
C. Mues
,
R. H. Strasser
Further Information

Publication History

Publication Date:
08 March 2016 (online)

Abstract

Direct oral anticoagulants (DOAC) are alternatives to vitamin K antagonists for prophylaxis of stroke in non-valvular atrial fibrillation and prophylaxis and therapy of venous thromboembolism. Currently there is a choice between the four DOACs Apixaban, Dabigatran, Edoxaban and Rivaroxaban. Strategies for differential therapy regarding indications, dosing, costs, drug interactions and cautions concerning impaired renal function are discussed briefly.